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Background
Health providers and thereby academy and industry is
challenged by gradually increasing demands from not at
least an ageing population, including increases in cancer,
cardiovascular and neurological diseases, diabetes, and
complex disease patterns with multimorbidity. At the
same time, economical restraints will not allow the society
to increase resources spent on health care.
Methods
The effects of the ageing population, changes in life style
(overweight, obesity, poor dietary habits, lack of physical
activity) needs to be dealt with. Demands from patients
are to improve quality of care and adding life to years
instead of just adding to your life. To provide European
citizens with lifelong health and wellbeing, visions for hori-
zon 2020 (and beyond) has been performed (Copenhagen
Research Forum). The global evolution in biomedicine will
provide access to new technologies that will require imple-
mentation. At the same time, as health care is a factor for
investment including industry, education and training is
also a possibility to create innovation and work in research
and improved health.
Results
Preventive measures will future on have large impact on
the health care situation and both clinical and transla-
tional research, including e.g. lifestyle, food intake, envir-
onmental factors. The willingness from the society to
spend more money on health care will be limited. The
ageing population will face advanced home care using
remote health monitoring, smart phones with medical
apps etc, rendering communication with health care
providers. Bioinformatics, advanced diagnostics, novel
combinations of therapies and improved knowledge on
the individual biological phenotypes (genomics, proteo-
mics, metabolomic profiles) will drive diagnosis and
treatment towards personalized medicine. The previously
long established “one-size fits all” concept will be
replaced by individualized and tailored management, i.e.
a true paradigm shift. Biobanks will be of substantial
help, providing e.g. novel biomarkers for diagnosis and
therapy.
Novel technologies bridging the fields of medicine and
technology/chemistry will provide us with e.g. nanome-
dicine, both for imaging and treatment, as well as artifi-
cial, bioartificial and tissue engineered organs.
Conclusions
The economical restraints future on will force us to trans-
lational and clinical research towards personalized medi-
cine (diagnostics and treatment), thereby steering efficient
therapy e.g. with companion diagnostics and increasing
cost effectiveness in health care. This paradigm shift will
demand academy and industry to provide completely
novel tools and thereby possibilities for innovation and
potential commercialization within life science in close
collaboration between health care, academy, and industry,
focusing on the patient’s need.
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